ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion

Ranibizumab (Fovlussea)

Treatment of neovascular (wet) age-related macular degeneration (AMD), and other visual impairments in adults

Biosimilar
CHMP opinion 15 Oct 2026 · Accord Healthcare S.L.U.
EU · EU licence (European Commission)

Ranibizumab (Susvimo)

Susvimo is indicated in adult patients for the treatment of neovascular (wet) age-related macular degeneration (nAMD) who have achieved stable disease after previously responding to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicinal product.

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

CHMP opinion 23 Jul 2026 → EU licence 18 Sept 2026 · Roche Registration GmbH
EU · EU licence (European Commission)

Ranibizumab (Vislyfa)

Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion… Show the full indication

Vislyfa is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV)

Biosimilar
CHMP opinion 21 May 2026 → EU licence 15 Jul 2026 · Lupin Europe GmbH
EU · EU licence (European Commission)

Ranibizumab (Rexatilux)

Rexatilux is indicated in adults for: - The treatment of neovascular (wet) age-related macular degeneration (AMD) - The treatment of visual impairment due to diabetic macular oedema (DME) - The treatment of proliferative diabetic retinopathy (PDR) - The treatment of visual impairment due to macular oedema secondary to retinal vein… Show the full indication

Rexatilux is indicated in adults for: - The treatment of neovascular (wet) age-related macular degeneration (AMD) - The treatment of visual impairment due to diabetic macular oedema (DME) - The treatment of proliferative diabetic retinopathy (PDR) - The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) - The treatment of visual impairment due to choroidal neovascularisation (CNV).

Biosimilar
CHMP opinion 23 Apr 2026 → EU licence 19 Jun 2026 · Intas Third Party Sales 2005 S.L.
EU · EU licence (European Commission)

Ranibizumab (Ranluspec)

Ranluspec is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion… Show the full indication

Ranluspec is indicated in adults for: The treatment of neovascular (wet) age-related macular degeneration (AMD) The treatment of visual impairment due to diabetic macular oedema (DME) The treatment of proliferative diabetic retinopathy (PDR) The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) The treatment of visual impairment due to choroidal neovascularisation (CNV) 

Biosimilar
CHMP opinion 11 Dec 2025 → EU licence 10 Feb 2026 · Lupin Europe GmbH

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.